TAILS N-terminomics of human platelets reveals pervasive metalloproteinase-dependent proteolytic processing in storage

Blood

Volumn 124, Issue 26, 2014, Pages e49-e60

  Prudova, Anna ^a,b   Serrano, Katherine ^a,c   Eckhard, Ulrich ^a,b   Fortelny, Nikolaus ^a,b   Devine, Dana V ^a,b,c   Overall, Christopher M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MARIMASTAT; METALLOPROTEINASE; METHIONINE; N TERMINOME; PEPTIDE; PROTEIN; PROTEINASE; PROTEOME; TERMINAL AMINE ISOTOPIC LABELING OF SUBSTRATE; UNCLASSIFIED DRUG; PEPTIDE HYDROLASE; PLASMA PROTEIN;

ACETYLATION; AMINO ACID SEQUENCE; ARTICLE; BLOOD BANK; BLOOD DONOR; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEOMICS; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; THROMBOCYTE SHAPE; THROMBOCYTE TRANSFUSION; THROMBOCYTE VOLUME; WESTERN BLOTTING; BLOOD STORAGE; ISOTOPE LABELING; LABORATORY DIAGNOSIS; METABOLISM; MOLECULAR GENETICS; PROCEDURES; PROTEIN TERTIARY STRUCTURE; THROMBOCYTE;

AMINO ACID SEQUENCE; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD PROTEINS; HUMANS; ISOTOPE LABELING; MASS SPECTROMETRY; METALLOPROTEASES; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; PROTEOME; PROTEOMICS; SPECIMEN HANDLING;

EID: 84919472207     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-569640     Document Type: Article

References (46)

1. Devine DV, Serrano K. The platelet storage lesion. Clin Lab Med. 2010;30(2):475-487.
2. Klinger MH. The storage lesion of platelets: ultrastructural and functional aspects. Ann Hematol. 1996;73(3):103-112.
3. Burkhart JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood. 2012;120(15):e73-e82.
4. Thiele T, Steil L, Gebhard S, et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion. 2007;47(7):1221-1233.
5. Thon JN, Schubert P, Duguay M, et al. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion. 2008;48(3):425-435.
6. Schubert P, Culibrk B, Karwal S, Slichter SJ, Devine DV. Optimization of platelet concentrate quality: application of proteomic technologies to donor management. J Proteomics. 2012;76(Spec No):329-336.
7. Thon JN, Devine DV. Translation of glycoprotein IIIa in stored blood platelets. Transfusion. 2007;47(12):2260-2270.
8. Schubert P, Thon JN, Walsh GM, et al. A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration. Transfusion. 2009;49(9):1944-1955.
9. Skripchenko A, Awatefe H, Thompson-Montgomery D, Myrup A, Turgeon A, Wagner SJ. An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion. PLoS ONE. 2013;8(8):e70732.
10. Doucet A, Butler GS, Rodríguez D, Prudova A, Overall CM. Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteomics. 2008;7(10):1925-1951.
11. Qiao JL, Shen Y, Gardiner EE, Andrews RK. Proteolysis of platelet receptors in humans and other species. Biol Chem. 2010;391(8):893-900.
12. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation. 2006;114(10):1070-1077.
13. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ. The mechanism of apoptosis in human platelets during storage. Transfusion. 2000;40(11):1320-1329.
14. Miletic VD, Popovic O. Complement activation in stored platelet concentrates. Transfusion. 1993;33(2):150-154.
15. Canault M, Duerschmied D, Brill A, et al. p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo. Blood. 2010;115(9):1835-1842.
16. Brown SB, Clarke MC, Magowan L, Sanderson H, Savill J. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem. 2000;275(8):5987-5996.
17. Bradley AJ, Read BL, Levin E, Devine DV. Small-molecule complement inhibitors cannot prevent the development of the platelet storage lesion. Transfusion. 2008;48(4):706-714.
18. Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003;102(12):4229-4235.
19. Morrison CJ, Butler GS, Rodríguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol. 2009;21(5):645-653.
20. Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res. 2008;121(4):535-542.
21. Bergmeier W, Piffath CL, Cheng G, et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res. 2004;95(7):677-683.
22. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007;5(7):1530-1537.
23. Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol. 2007;8(3):245-257.
24. Wildes D, Wells JA. Sampling the N-terminal proteome of human blood. Proc Natl Acad Sci USA. 2010;107(10):4561-4566.
25. Gevaert K, Goethals M, Martens L, et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003;21(5):566-569.
26. Dix MM, Simon GM, Cravatt BF. Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell. 2008;134(4):679-691.
27. Kleifeld O, Doucet A, auf dem Keller U, et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat Biotechnol. 2010;28(3):281-288.
28. Prudova A, auf dem Keller U, Butler GS, Overall CM. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics. 2010;9(5):894-911.
29. auf dem Keller U, Prudova A, Eckhard U, Fingleton B, Overall CM. Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation. Sci Signal. 2013;6(258):rs2.
30. Vizcaíno JA, Côté RG, Csordas A, et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013;41(Database issue): D1063-D1069.
31. Yasui M, Kwon TH, Knepper MA, Nielsen S, Agre P. Aquaporin-6: An intracellular vesicle water channel protein in renal epithelia. Proc Natl Acad Sci USA. 1999;96(10):5808-5813.
32. Lane L, Bairoch A, Beavis RC, et al. Metrics for the Human Proteome Project 2013-2014 and strategies for finding missing proteins. J Proteome Res. 2014;13(1):15-20.
33. Martens L, Van Damme P, Van Damme J, et al. The human platelet proteome mapped by peptide-centric proteomics: a functional protein profile. Proteomics. 2005;5(12):3193-3204.
34. Lange PF, Huesgen PF, Nguyen K, Overall CM. Annotating N termini for the human proteome project: N termini and Na-acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome. J Proteome Res. 2014;13(4):2028-2044.
35. Paik YK, Omenn GS, Uhlen M, et al. Standard guidelines for the chromosome-centric human proteome project. J Proteome Res. 2012;11(4):2005-2013.
36. Agard NJ, Wells JA. Methods for the proteomic identification of protease substrates. Curr Opin Chem Biol. 2009;13(5-6):503-509.
37. Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. Proc Natl Acad Sci USA. 2010;107(4):1488-1493.
38. Weyrich AS, Dixon DA, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA. 1998;95(10):5556-5561.
39. Ozaki Y, Suzuki-Inoue K, Inoue O. Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. J Thromb Haemost. 2013;11(suppl 1):330-339.
40. Bergmeier W, Piffath CL, Goerge T, et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA. 2006;103(45):16900-16905.
41. Coller BS, Kalomiris E, Steinberg M, Scudder LE. Evidence that glycocalicin circulates in normal plasma. J Clin Invest. 1984;73(3):794-799.
42. Wolff V, Aleil B, Giroud M, et al. Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke. 2005;36(3):e17-e19.
43. Aleil B, Meyer N, Wolff V, et al. Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost. 2006;96(4):505-511.
44. Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004;104(5):1350-1355.
45. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004;22(23):4683-4690.
46. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2(9):657-672.